Showing results (211-220 of 253) with videos related to
Sort By:
Pageof 26
The Review of Scientific Instruments|March 2, 2022
SiAl composite feedhorn arrays for astrophysical applications: Cryogenic material propertiesAamir M Ali, Thomas Essinger-Hileman, Tobias Marriage, et al.Journal of Palliative Medicine|October 14, 2009
Feasibility and effectiveness of the NEST13+ as a screening tool for advanced illness care needsKaren G Scandrett, Eva B Reitschuler-Cross, Lauren Nelson, et al.The Lancet. Oncology|November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jawBeatrice J Edwards, Mrinal Gounder, June M McKoy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylateDavid A Dorr, Rachel Burdon, Dennis P West, et al.Cancer Medicine|June 22, 2017
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Rachel A Sabol, Virginia Noxon, Oliver Sartor, et al.Seminars in Thrombosis and Hemostasis|November 1, 2012
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, David M Spiegel, Iain C Macdougall, et al.The Lancet. Oncology|December 3, 2020
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse ReactionsCharles L Bennett, Martin W Schoen, Shamia Hoque, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.British Journal of Haematology|October 24, 2006
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett, Andrew M Evens, Leslie A Andritsos, et al.Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.Pageof 26